CNS Pharmaceuticals

CNSP

Börsenwert 7,09 Mio. $

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on its business development strategy as part of its broader transformation as the Company works to establish a pipeline focused on oncology or neurology with best in class potential.

Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of its newly assembled executive leadership team, enhanced financial position following its recent financing, and disciplined approach to evaluating differentiated assets.

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026. "We are moving with speed and discipline to transform this company," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals.

Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation.

Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.

CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company's ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287.

CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Wednesday's premarket session.

CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Monday's premarket session following the announcement of an oversubscribed private placement financing expected to generate approximately $22.5 million.